title: Cystic Fibrosis Papers of the Year 2015.
abstract: Studies published in the last year have expanded our knowledge of potential disease modifying agents in the treatment of class II, III and IV CFTR mutations, and included the first report of an efficacious gene therapy for CF. There is also an important message on increasing use of conventional chronic therapies even in milder disease, and the pernicious effect of chronic infection on pulmonary function.
authors.affiliation: Department of Paediatric Respiratory Medicine and Paediatric, Cystic Fibrosis Centre, Children's Hospital for Wales, Cardiff, CF14 4XN, UK. Electronic address: doullij@cf.ac.uk.
authors.forename: Iolo
authors.initials: I
authors.lastname: Doull
mesh_terms: D015706:Bibliometrics; D003550:Cystic Fibrosis / Q000453:epidemiology / Q000382:microbiology / Q000503:physiopathology / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans; D017063:Outcome Assessment, Health Care; D012129:Respiratory Function Tests
keywords: Cystic fibrosis; Gene therapy; Ivacaftor; Lumacaftor